The nitric oxide donor JS-K sensitizes U87 glioma cells to repetitive irradiation

As a potent radiosensitizer nitric oxide (NO) may be a putative adjuvant in the treatment of malignant gliomas which are known for their radio- and chemoresistance. The NO donor prodrug JS-K (O2-(2.4-dinitrophenyl) 1-[(4-ethoxycarbonyl) piperazin-1-yl] diazen-1-ium-1,2-diolate) allows cell-type specific intracellular NO release via enzymatic activation by glutathione-S-transferases overexpressed in glioblastoma multiforme. The cytotoxic and radiosensitizing efficacy of JS-K was assessed in U87 glioma cells in vitro focusing on cell proliferation, induction of DNA damage, and cell death. In vivo efficacy of JS-K and repetitive irradiation were investigated in an orthotopic U87 xenograft model in mice. For the first time, we could show that JS-K acts as a potent cytotoxic and radiosensitizing agent in U87 cells in vitro. This dose- and time-dependent effect is due to an enhanced induction of DNA double-strand breaks leading to mitotic catastrophe as the dominant form of cell death. However, this potent cytotoxic and radiosensitizing effect could not be confirmed in an intracranial U87 xenograft model, possibly due to insufficient delivery into the brain. Although NO donor treatment was well tolerated, neither a retardation of tumor growth nor an extended survival could be observed after JS-K and/or radiotherapy.

• Publication year

  2017

• Venue

  Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

• Publication date

  2017-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1177/1010428317703922PMID 28653883
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ATF3 reduces migration capacity by regulation of matrix metalloproteinases via NFκB and STAT3 inhibition in glioblastoma

  2017cited by this paper
• Nitric oxide released from JS-K induces cell death by mitotic catastrophe as part of necrosis in glioblastoma multiforme

  2016cited by this paper
• Blood Brain Barrier: A Challenge for Effectual Therapy of Brain Tumors

  2015cited by this paper
• Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

  2014cited by this paper
• Increased sensitivity to ionizing radiation by targeting the homologous recombination pathway in glioma initiating cells

  2014cited by this paper
• Radiation-induced mitotic cell death and glioblastoma radioresistance: a new regulating pathway controlled by integrin-linked kinase, hypoxia-inducible factor 1 alpha and survivin in U87 cells.

  2013cited by this paper
• Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI.

  2013cited by this paper
• JS-K, a Glutathione S-Transferase–Activated Nitric Oxide Donor With Antineoplastic Activity in Malignant Gliomas

  2012cited by this paper
• Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review.

  2012cited by this paper
• Growth‐inhibitory and chemosensitizing effects of the glutathione‐S‐transferase‐π‐activated nitric oxide donor PABA/NO in malignant gliomas

  2012cited by this paper
• Nitric oxide synthases: regulation and function.

  2012cited by this paper
• Delayed cell death associated with mitotic catastrophe in γ-irradiated stem-like glioma cells

  2011cited by this paper
• Differential effects of nitric oxide on blood-brain barrier integrity and cerebral blood flow in intracerebral C6 gliomas.

  2011cited by this paper
• DNA strand breaks and hypoxia response inhibition mediate the radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions.

  2011cited by this paper
• The Nitric Oxide Prodrug JS-K Is Effective against Non–Small-Cell Lung Cancer Cells In Vitro and In Vivo: Involvement of Reactive Oxygen Species

  2011cited by this paper
• Radiation-induced cell death mechanisms

  2010cited by this paper
• DNA Repair and Resistance of Gliomas to Chemotherapy and Radiotherapy

  2009cited by this paper
• Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies

  2009cited by this paper
• Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid leukemia cells.

  2009cited by this paper
• Heterogeneity of Human Glioblastoma: Glutathione-S-Transferase and Methylguanine-Methyltransferase

  2008cited by this paper
• Hypoxic tumor cell radiosensitization through nitric oxide.

  2008cited by this paper
• JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.

  2007cited by this paper
• Tumors face NO problems?

  2006cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-κB and inhibition of Bcl-xL expression

  2004cited by this paper
• Nitric Oxide and Ionizing Radiation Synergistically Promote Apoptosis and Growth Inhibition of Cancer by Activating p53

  2004cited by this paper
• ATM: Ready, Set, Go

  2003cited by this paper
• Selective opening of the blood-tumor barrier by a nitric oxide donor and long-term survival in rats with C6 gliomas.

  2003cited by this paper
• JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity.

  2003cited by this paper
• Sensing and repairing DNA double-strand breaks.

  2002cited by this paper
• Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.

  2002cited by this paper
• Characterization of the necrotic cleavage of poly(ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases

  2001cited by this paper
• Effects of

  2000cited by this paper
• Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy.

  2000cited by this paper
• Growth Inhibition and Radiosensitization of Cultured Glioma Cells by Nitric Oxide Generating Agents

  1999cited by this paper
• Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations.

  1998cited by this paper
• Intrinsic radiosensitivity of human pancreatic tumour cells and the radiosensitising potency of the nitric oxide donor sodium nitroprusside.

  1996cited by this paper
• Role of nitric oxide and its interaction with superoxide in the suppression of cardiac muscle mitochondrial respiration. Involvement in response to hypoxia/reoxygenation.

  1996cited by this paper
• Radiation sensitisation by nitric oxide releasing agents.

  1996cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper

• JS-K enhances renal cell carcinoma radiosensitivity through the Wnt/β-catenin signaling pathway and inhibits DNA damage repair.

  2025cites this paper
• Pivotal Role of Cranial Irradiation-Induced Peripheral, Intrinsic, and Brain-Engrafting Macrophages in Malignant Glioma

  2024cites this paper
• Pharmacotherapeutic Potential of Bitter Gourd (Momordica charantia) in Age-related Neurological Diseases.

  2024cites this paper
• Nitric Oxide Prevents Glioblastoma Stem Cells’ Expansion and Induces Temozolomide Sensitization

  2023cites this paper
• Supramolecular Nitric Oxide Depot for Hypoxic Tumor Vessel Normalization and Radiosensitization

  2022cites this paper
• Harnessing oxidative stress for anti-glioma therapy.

  2022cites this paper
• Cancer nanotechnology: current status and perspectives

  2021cites this paper
• Exogenous NO induces apoptosis of hepatocellular carcinoma cells via positive p38/JNK signaling pathway and negative ERK signaling pathways

  2021cites this paper
• Protective role of natural products in glioblastoma multiforme: A focus on nitric oxide pathway.

  2020cites this paper
• Nitric Oxide-Mediated Enhancement and Reversal of Resistance of Anticancer Therapies

  2019cites this paper
• Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible.

  2019cites this paper
• MAP30 promotes apoptosis of U251 and U87 cells by suppressing the LGR5 and Wnt/β-catenin signaling pathway, and enhancing Smac expression.

  2018cites this paper
• M2 macrophages are more resistant than M1 macrophages following radiation therapy in the context of glioblastoma

  2017influential citation